glp-1 covered by insurance Perspectives from employers on the costs and issues associated with covering agonists for weight loss GLP-1 Coverage in Employer Plans
Description
Prescription Type 17.13.5
Similarly, tirzepatide is more effective at supporting weight loss than semaglutide but seems to have a poorer safety profile
Perkovic V et al
For employer carve-outs, the appeal pathway is closed because the benefit comes from the plan document
Introduction The obesity and metabolic disease epidemic continues to surge, with over 40% of U.S
Patients with obese HFpEF who had T2DM or not received treatment with GLP-1 agonists in STEP-HFpEF trials which showed KCCQ score improvements of +16.6 points and weight loss of 13% and reduced HF hospitalization rates by 79% [11,56]
